Skip to main content
. 2022 Jun;17(6):922–933. doi: 10.2215/CJN.14671121

Table 2.

Reported cases of renal tubular acidosis with use of immune checkpoint inhibitors

Reported Case Renal Tubular Acidosis Type AKI Cancer Immune Checkpoint Inhibitor Serum pH Serum Potassium, mEq/L Serum Phosphate, mg/dl Urine pH Urine Anion Gap Kidney Biopsy Treatment Outcome Ref.
1 Proximal No HCC N 7.39 1.7 1.2 7.0 NR Not performed Electrolyte replacement of potassium phosphate ICI held, acidosis improved 44
2 Proximal Yes Lung P NR 2.5 1.5 NR NR Not performed Electrolyte replacement of potassium, phosphate, magnesium, and iv steroids ICI was held, resolution of electrolyte abnormalities 45
3 Proximal Yes Lung N/P 7.35 4.5 2.3 NR NR Not performed iv bicarbonate therapy and prednisone ICI held, resolution of electrolyte abnormalities 46
4 Proximal Yes Melanoma I/N NR 1.7 NR NR NR Not performed iv bicarbonate, steroids and electrolyte replacement Presented with hypokalemia and paralysis that resolved, rechallenged with P 43
5 Distal Yes Lung N 7.21 2.4 NR 6.5 22 Not performed iv bicarbonate therapy, and dexamethasone 4 mg every 8 h ICI held 94
6 Distal Yes Lung P 7.26 2.8 NR 6.5 10 Tubulointerstitial nephritis Oral sodium bicarbonate, prednisone AKI, acidosis improved 90
7 Distal Yes Melanoma N 7.25 4.2 NR 6.3 48 Acute and chronic tubulointerstitial nephritis iv normal saline, oral potassium citrate, prednisone AKI, acidosis improved 90
8 Distal Yes RCC N 7.23 3.9 NR 6.7 NR Not performed Prednisone, oral sodium bicarbonate ICI held, AKI, acidosis improved 90
9 Distal No Lung N/P 7.29 3.3 NR 6.0 36 Interstitial edema, tubulitis of DCT and collecting ducts Initially oral bicarbonate for a week, then initiated on steroids 1mg/kg per d ICI held, acidosis improved 89
10 Distal Yes Melanoma P 7.05 3.2 NR 6.0 49 Not performed iv and oral bicarbonate supplementation, prednisone ×15 d ICI held, acidosis improved 95
11 Distal No Melanoma P NR 3.6 2.6 6.0 8 Not performed iv and oral steroids Acidosis improved 96

HCC, hepatocellular carcinoma; N, nivolumab; NR, not reported; ICI, immune checkpoint inhibitor; P, pembrolizumab; iv, intravenous; RCC, renal cell cancer; I, ipilimumab; DCT, distal convoluted tubule.